Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication

H. B. Yang, H. C. Cheng, B. S. Sheu, K. H. Hung, M. F. Liou, J. J. Wu

研究成果: Article同行評審

42 引文 斯高帕斯(Scopus)

摘要

Background and Aim: To test whether the chronic users of celecoxib, a selective cyclo-oxygenase-2 inhibitor, had less Helicobacter pylori-related intestinal metaplasia or if such users' intestinal metaplasia could be prone to disappear after H. pylori eradication. Methods: The study enrolled 150 chronic celecoxib users and 216 non-users who underwent pan-endoscopy to detect H. pylori infection and its related intestinal metaplasia. One hundred and three H. pylori-infected patients with intestinal metaplasia (43 chronic celecoxib users and 60 non-users) received anti-H. pylori therapy and completed the 12-month follow-up to survey the regression of intestinal metaplasia by mean intestinal metaplasia score. Results: There were no differences in the prevalence of H. pylori-related intestinal metaplasia between the chronic celecoxib users and controls (P > 0.05). On the 12th month of follow-up, chronic celecoxib users had a lower mean intestinal metaplasia score (1.2 vs. 1.8, P < 0.005) and a higher regression rate of intestinal metaplasia (42% vs. 20%, P = 0.027) than non-users. Conclusions: With H. pylori infection, chronic celecoxib users still showed limited effects to decrease intestinal metaplasia. Nevertheless, celecoxib should be promising to assist H. pylori eradication for the control of gastric intestinal metaplasia and cancer risk.

原文English
頁(從 - 到)455-461
頁數7
期刊Alimentary Pharmacology and Therapeutics
25
發行號4
DOIs
出版狀態Published - 2007 2月

All Science Journal Classification (ASJC) codes

  • 肝病
  • 消化內科
  • 藥學(醫學)

指紋

深入研究「Chronic celecoxib users more often show regression of gastric intestinal metaplasia after Helicobacter pylori eradication」主題。共同形成了獨特的指紋。

引用此